Faced with slowing demand, 23andMe cuts 100 employees
The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.
The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.
Separately, the next-generation sequencing manufacturer will also work with Genomics England to sequence up to 300,000 people over the next five years.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Federal Trade Commission had accused Illumina of seeking to monopolize the market for next-generation sequencing in its effort to acquire Pacific Biosciences, originally announced in November 2018.
Federal regulators said they would seek to block the acquisition deal amid concerns that Illumina was seeking to eliminate PacBio as a competitor in the next-generation sequencing space.
The company's valuation has declined 80 percent, from a $1.6 billion peak to $310 million, according to The Wall Street Journal.
In January 2016, Independence Blue Cross and NantHealth announced the nation's first coverage for a whole genome sequencing and proteome molecular diagnostic platform, but it's mostly slipped under the radar since then. What's going on?
The company plans to bring NGS to health systems lacking the ability to perform it internally.
Next-generation sequencing firm plans to present data on its gargantuan genomics study at ASCO next month.
Helix and Illumina Accelerator have paired up and will give entrepreneurs the chance to develop innovative, DNA-driven products geared toward consumers.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Illumina spin-out Grail revealed Wednesday that Jeff Huber is stepping down as CEO of the billion-dollar early cancer detection startup.
The results of the study will serve as a baseline measure for detecting breast cancer in the blood and inform the development of Grail's pan-cancer screening test.
With a billion dollars in private financing and a test projected to generate a terabyte of data per person, Grail has seeded a new category of diagnostics and Big Data. Despite this, the company story shared by CEO Jeff Huber is mostly about people.
This was but one of several pieces of news the Amsterdam-based technology company discussed Monday at HIMSS17.
The leader of the sequencing world is ticking over nicely with sales and revenue, according to Tuesday's earnings call. But what's happening behind the scenes? Here we take a look at five trends shaping the future of the company.